Effects of Modified Constraint-Induced Movement Therapy and Mirror Therapy in Hemiplegic Stroke
Condition(s) studied
Investigational drug(s) / intervention(s)
Mirror Therapy: Mirror therapy protocols targeting upper extremity motor functions for 4 weeks.
Modified Constraint-Induced Movement Therapy: Modified constraint-induced movement therapy (modified CIMT) protocols targeting the affected upper extremity for 4 weeks.
Study summary
The purpose of this study is to investigate and compare the effects of Modified Constraint-Induced Movement Therapy (mCIMT) and Mirror Therapy (MT) on upper extremity motor functions, activity participation, and independence in daily living activities among hemiplegic stroke patients. Participants diagnosed with stroke will be randomly assigned to intervention groups. The study aims to determine which therapeutic modality provides a higher contribution to the functional recovery of the paretic upper limb and overall quality of life.
Eligibility
Primary outcome measure(s)
- Fugl-Meyer Assessment-Upper Extremity (FMA-UE) — Baseline (pre-treatment) and 4 weeks (post-treatment)
The FMA-UE is an index used to assess sensorimotor function in stroke patients. It evaluates reflex activity, volitional movement, and coordination of the upper extremity. The total score ranges from 0 to 66, with higher scores indicating better upper extremity motor function. - Stroke Rehabilitation Assessment of Movement (STREAM) — Baseline (pre-treatment) and 4 weeks (post-treatment)
The STREAM is a clinical measure of motor functioning for stroke patients. It evaluates upper limb movements, lower limb movements, and basic mobility. The total score ranges from 0 to 30 for each subscale, with higher scores reflecting better motor performance and mobility.
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Akay Special Education and Rehabilitation Center | Kastamonu | Merkez | Recruiting |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07668349 on ClinicalTrials.gov ↗ ← All trials in Turkey